Clinical trials: Leukemia, Lymphocytic, Acute, T-Cell
Lymphoma
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
RATIONALE: Giving high-dose chemotherapy drugs, such as carmustine, etoposide, and cyclophosphamide, before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00641381
- Testing
- carmustine, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia
Experimental Bone Marrow Transplant Protocol
Bone marrow transplantation (BMT) is a risky procedure. If doctors could reduce the complications, BMT would be safer to use for a wider range of conditions.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myelocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00061581
- Testing
- Isolex 300i Stem Cell Selection
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Leukemia
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim and sargramostim may increase the number of immune cells found…
- Trial name
- NCT00053131
- Testing
- filgrastim, sargramostim, cytarabine
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Acute Lymphobkastic Leukemia
Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL
Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, relapse after CAR-T has been a major issue.
- Trial name
- NCT06985498
- Testing
- Sandwich stratergy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
B-cell Acute Lymphoblastic Leukemia
Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
This is a single-center, open-label, single-arm prospective study designed to evaluate the safety, tolerability, and efficacy of dual-target CD22/CD19 chimeric antigen receptor (CAR)-T cell therapy as consolidation treatment in…
- Trial name
- NCT07575919
- Testing
- CD22/CD19 Dual-Target CAR-T Cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Liping Dou
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
This study examines the safety, tolerability and preliminary efficacy of anti-CD19 /CD22 CAR T cells (KQ-2002)manufactured on-site in adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell…
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
- Trial name
- NCT06445803
- Testing
- KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Rong Tao
Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia
This study is a phase I study designed to evaluate the safety of CD19-CD22-CAR T cells. Primary Objective: To determine the safety profile and propose the recommended phase 2 dose (RP2D) of autologous CD19-CD22-CAR T cells in…
- Conditions
- Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
- Trial name
- NCT06777979
- Testing
- Fludarabine, Cyclophosphamide, Mesna
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- St. Jude Children's Research Hospital
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of dasatinib in treating patients with solid tumors or lymphomas that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia, Adult Hepatocellular Carcinoma, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
- Trial name
- NCT00608361
- Testing
- Dasatinib, Pharmacological Study
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- LAL1308 (NCT01156883)
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 43 sites in Italy
- Volunteers
- 76 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
This phase I clinical trial is studying the side effects and best dose of RO4929097 when given together with capecitabine in treating patients with refractory solid tumors.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma
- Trial name
- NCT01158274
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis
- Where
- 2 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
Phase I trial to study the effectiveness of SB-715992 in treating patients who have acute leukemia, chronic myelogenous leukemia, or advanced myelodysplastic syndromes.
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00098826
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Adult T-cell Leukemia/Lymphoma
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
ETP-ALL like patients have poor outcomes and prognosis, and the optimal therapeutic approaches are poorly characterized. The goal of this clinical trial is to evaluate the efficacy and safety of the venetoclax combined with…
- Trial name
- NCT07159620
- Testing
- VEN (Venetoclax), Azacitidine (AZA), Chidamide
- Where
- China
- Volunteers
- 27 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
To observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/NHL
- Conditions
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma, PTCL
- Trial name
- Phase I/II (NCT06874946)
- Testing
- CD5-targeted CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
This is a phase l, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients.
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
- Trial name
- CARTHIAE-1 (NCT05705570)
- Testing
- Cyclophosphamide, Fludarabine, Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Nelson Hamerschlak
Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission
Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma
This is a single-arm open-label phase I/II study to determine the relative superiority of αCD19-TCRζ-CD28 and αCD19-TCRζ-CD137 CAR-T Cells in safety, efficacy and engraftment potential in patients with CD19+ B-lineage leukemia…
- Conditions
- Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia
- Trial name
- MatchCART (NCT02685670)
- Testing
- anti-CD19 CAR-T, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Leukemia, Lymphoma
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Aldesleukin may stimulate natural killer cells to kill cancer cells. Treating natural killer cells with aldesleukin in the laboratory may help the natural killer cells kill more cancer cells when they are put back in…
- Trial name
- NCT00625729
- Testing
- aldesleukin, allogeneic natural killer cells, rituximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Lymphoma
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00002502
- Testing
- busulfan, cyclophosphamide, cytarabine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134004
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.